Stent Thrombosis Redux — The FDA Perspective
Top Cited Papers
- 8 March 2007
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (10) , 984-987
- https://doi.org/10.1056/nejmp068304
Abstract
In the light of recent studies suggesting that drug-eluting stents may pose a risk of thrombosis that was not observed during pre-market testing, the Food and Drug Administration (FDA) convened a meeting of its Circulatory System Devices Advisory Panel on December 7 and 8, 2006, to examine the safety of these devices. The FDA will carefully consider the information and views presented at the meeting in deciding on future actions.Keywords
This publication has 2 references indexed in Scilit:
- Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent ImplantationJAMA, 2007
- Problems with Drug-Eluting Coronary Stents — The FDA PerspectiveNew England Journal of Medicine, 2004